It is commonly believed that metformin exerts its anti-cancer activity via the LKB1–AMPK–mTOR pathway, and the overexpression of mTOR in this pathway is often associated with the development of numerous diseases such as tumors, among others [86,87,88,89,90]. This evidence concerns the gene MTOR and cancer.